Druva Sarika Rongala,Suyash M. Patil,Nitesh K. Kunda
Abstract:Tuberculosis (TB) is an airborne bacterial infection caused by Mycobacterium tuberculosis (M. tb), resulting in approximately 1.3 million deaths in 2022 worldwide. Oral therapy with anti-TB drugs often fails to achieve therapeutic concentrations at the primary infection site (lungs). In this study, we developed a dry powder inhalable formulation (DPI) of clofazimine (CFZ) to provide localized drug delivery and minimize systemic adverse effects. Poly (lactic acid-co-glycolic acid) (PLGA) microparticles (MPs) containing CFZ were developed through a single emulsion solvent evaporation technique. Clofazimine microparticles (CFZ MPs) displayed entrapment efficiency and drug loading of 66.40 ± 2.22 %w/w and 33.06 ± 1.45 μg/mg, respectively. To facilitate pulmonary administration, MPs suspension was spray-dried to yield a dry powder formulation (CFZ SD MPs). Spray drying had no influence on particle size (~1 μm), zeta potential (−31.42 mV), and entrapment efficiency. Solid state analysis (PXRD and DSC) of CFZ SD MPs studies demonstrated encapsulation of the drug in the polymer. The drug release studies showed a sustained drug release. The optimized formulation exhibited excellent aerosolization properties, suggesting effective deposition in the deeper lung region. The in vitro antibacterial studies against H37Ra revealed improved (eight-fold) efficacy of spray-dried formulation in comparison to free drug. Hence, clofazimine dry powder formulation presents immense potential for the treatment of tuberculosis with localized pulmonary delivery and improved patient compliance.
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to develop an inhalable PLGA microparticle - drug - loading system for tuberculosis treatment, in order to provide local drug delivery and reduce systemic side effects. Specifically, the research aims to optimize the spray - drying process parameters through the Design of Experiments (DoE) method, prepare PLGA microparticles loaded with Clofazimine (CFZ), and make them into a Dry Powder Inhaler (DPI) to improve the drug delivery efficiency and treatment effect in the lungs.
### Main research background and problems
1. **The current situation of tuberculosis**:
- Tuberculosis is an airborne infection caused by Mycobacterium tuberculosis (M. tb), which causes about 1.3 million deaths every year.
- Oral anti - tuberculosis drugs are usually difficult to reach the therapeutic concentration at the main infection site (the lungs), and long - term high - dose treatment is required, which may lead to poor patient compliance and the development of multi - drug - resistant tuberculosis (MDR - TB).
2. **Characteristics of Clofazimine (CFZ)**:
- CFZ is a poorly water - soluble antibiotic and anti - inflammatory drug, which is highly active against a variety of mycobacteria, including Mycobacterium tuberculosis.
- At present, it is mainly used for the treatment of leprosy in clinical practice, and is also recommended as a second - line treatment drug for MDR - TB.
- High oral doses of CFZ can cause serious side effects, such as skin and conjunctiva discoloration, cardiotoxicity, gastrointestinal discomfort, etc.
3. **Advantages of inhalable drug delivery**:
- Pulmonary administration can achieve direct drug delivery to the lungs, reach effective pulmonary concentrations, and reduce systemic side effects.
- Compared with traditional oral administration, inhalable administration requires a lower dose, a shorter treatment time, and a lower administration frequency.
- Dry Powder Inhaler (DPI) has the advantages of high stability, easy handling, and portability.
### Research objectives
- **Develop PLGA microparticles loaded with CFZ**: Prepare PLGA microparticles loaded with CFZ (CFZ MPs) through the single - emulsion solvent evaporation technique, and optimize their encapsulation efficiency and drug loading.
- **Spray - drying optimization**: Use the Box - Behnken design method to optimize the spray - drying process parameters, such as inlet air temperature, suction settings, and feed rate, to prepare a stable dry powder inhaler (CFZ SD MPs).
- **Characterization and evaluation**: Characterize the prepared CFZ SD MPs, including particle size, Zeta potential, encapsulation efficiency, drug loading, in vitro aerosol performance, and in vitro antibacterial activity.
### Solved problems
- **Improve drug delivery efficiency**: Through inhalable administration, make the drug reach the lungs directly, increase the local drug concentration, and reduce systemic side effects.
- **Optimize the spray - drying process**: Through the Design of Experiments method, find the best spray - drying parameters to ensure that the prepared dry powder has good stability and dispersibility.
- **Verify drug activity**: Verify the antibacterial activity of CFZ SD MPs through in vitro experiments to prove its effectiveness in the lungs.
In conclusion, this paper aims to provide a more effective and safer tuberculosis treatment method by developing and optimizing the inhalable PLGA microparticle - drug - loading system.